Reshaped human antibody to human interleukin-6

• US 5,856,135 A
• Filed: 02/20/1996
• Issued: 01/05/1999
• Est. Priority Date: 05/31/1993
• Status: Expired due to Fees

• Current Assignee: Chugai Seiyaku Kabushiki Kaisha (Roche Holding AG)
• Original Assignee: Chugai Seiyaku Kabushiki Kaisha (Roche Holding AG)
• Inventors: Hirata, Yuichi, Tsuchiya, Masayuki, Sato, Koh
• Primary Examiner(s): Hutzell, Paula K.
• Assistant Examiner(s): Vavarro, Mark
• Application Number:
  US08/553,501
• Time in Patent Office: 1,050 Days
• Field of Search: 536/23.53, 435/320.1, 435/326, 435/328, 435/335, 435/69.3, 435/69.6, 435/70.21, 435/332
• US Class Current: 435/69.3
• CPC Class Codes: C07K 16/00 Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies antibodies with enzymatic activity, e.g. abzymes C12N9/0002
• CPC Class Codes: C07K 16/248 IL-6
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/56 variable (Fv) region, i.e. VH and/or VL
• CPC Class Codes: C07K 2317/565 Complementarity determining region [CDR]
• CPC Class Codes: C07K 2319/00 Fusion polypeptide

Abstract

A reshaped antibody comprising:

(A) L chains comprising:

(1) a human C region, and

(2) an L chain V region comprising human L chain FRs and L chain CDRs of a mouse monoclonal antibody; and

(B) H chains comprising:

(1) a human H chain C region, and

(2) an H chain V region comprising human H chain FRs, and H chain cDRs of a mouse monoclonal antibody to human IL-6. Since the major portions of the reshaped human antibody are derived from human, and the mouse CDRs are less immunogenic, then the present reshaped human antibody is less immunogenic, and therefore inhibits information transfer by IL-6, and is promising as a therapeutic agent for diseases caused by IL-6.

Claims

1. A DNA sequence coding for a light (L) chain of an antibody to human interleukin-6, wherein the L chain comprises an L chain variable (V) region and a human L chain constant (C) region;

wherein the L chain V region is represented by the formula (I);

space="preserve" listing-type="equation">FR.sub.L 1-CDR.sub.L 1-FR.sub.L 2-CDR.sub.L 2-FR.sub.L 3-CDR.sub.L 3-FR.sub.L 4

wherein the FR_L 1, FR_L 2, FR_L 3 and FR_L 4 have the following amino acid sequences respectively;

FR_L 1;

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys (SEQ ID No;

     69);

FR_L 2;

Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr (SEQ ID NO;

     70);

FR_L 3;

Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys (SEQ ID NO;

     71); and

FR_L 4;

Phe Gly Gln Gly Thr Lys Val Glu Ile Lys (SEQ ID NO;

     72);

and the CDR_L 1, CDR_L 2 and CDR_L 3 have the following amino acid sequences respectively;

CDR_L 1;

Arg Ala Ser Glu Asn Ile Tyr Ser Asn Leu Ala (SEQ ID NO;

     62)

CDR_L 2;

Ala Ala Thr Tyr Leu Ala Asp (SEQ ID NO;

     63)

CDR_L 3;

Gln His Phe Trp Gly Thr Pro Pro (SEQ ID NO;

     64) or

wherein the L chain V region is represented by the nucleotide sequence shown in SEQ ID NO;

56.

5. The DNA sequence according to claim 1, wherein the L chain V region comprises SEQ ID NO:

56.

6. A recombinant vector comprising the DNA sequence according to SEQ ID NO:

56 or claim 1.

7. An isolated transformant cotransformed with a recombinant vector according to claim 6 and a recombinant vector comprising a DNA sequence coding for an H chain of an antibody to human interleukin-6, wherein the H chain comprises an H chain V region and a human H chain C region and the H chain V region is represented by the formula (II):

space="preserve" listing-type="equation">FR.sub.H 1-CDR.sub.H 1-FR.sub.H 2-CDR.sub.H 2-FR.sub.H 3-CDR.sub.H 3-FR.sub.H 4

wherein the FR_H 1, FR_H 2, FR_H 3 and FR_H 4 have one of sets ((a) or (b)) of the following amino acid sequences respectively;

(a) FR_H 1;

Gln Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Arg Pro Thr Gln Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser (SEQ ID NO;

     76);

FR_H 2;

Trp Ile Arg Gln Pro Pro Gly Glu Ala Leu Glu Trp Leu Ala (SEQ ID NO;

     77);

FR_H 3;

Arg Leu Ala Val Ser Lys Asp Thr Ser Lys Asn Gln Val Val Leu Ser Met Asn Thr Val Gly Pro Gly Asp Thr Ala Thr Tyr Tyr Cys Ala Arg (SEQ ID NO;

     78); and

FR_H 4;

Trp Gly Gln Gly Ile Leu Val Thr Val Ser Ser (SEQ ID NO;

     79) or

(b) FR_H 1;

Gln Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Arg Pro Thr Gln Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Asn (SEQ ID NO;

     80);

FR_H 2;

Trp Ile Arg Gln Pro Pro Gly Glu Ala Leu Glu Trp Leu Ala (SEQ ID NO;

     81);

FR_H 3;

Arg Leu Ala Val Ser Lys Asp Thr Ser Lys Asn Gln Val Val Leu Ser Met Asn Thr Val Gly Pro Gly Asp Thr Ala Thr Tyr Tyr Cys Ala Arg (SEQ ID NO;

     82); and

FR_H 4;

Trp Gly Gln Gly Ile Leu Val Thr Val Ser Ser (SEQ ID NO;

     83);

and the CDR_H 1, CDR_H 2, and CDR_H 3 have the following amino acid sequences respectively;

CDR_H 1;

Thr Ser Gly Met Thr Val Gly (SEQ ID NO;

     73);

CDR_H 2;

His Ile Trp Trp Asn Asp Asp Lys Tyr Tyr Asn Pro Ala Leu Lys Gly (SEQ ID NO;

     74);

CDR_H 3;

Met Glu Asp Tyr Asp Glu Ala Met Asp Tyr (SEQ ID NO;

     75) or

wherein the H chain V region comprises the nucleotide sequence shown in SEQ ID NO;

60.

2. A recombinant vector comprising:

the DNA sequence coding for a light (L) chain of an antibody to human interleukin-6, wherein the L chain comprises an L chain variable (V) region and a human L chain constant (C) region;

wherein the L chain V region is represented by the formula (I);

space="preserve" listing-type="equation">FR.sub.L 1-CDR.sub.L 1-FR.sub.L 2-CDR.sub.L 2-FR.sub.L 3-CDR.sub.L 3-FR.sub.L 4

wherein the FR_L 1, FR_L 2, FR_L 3 and FR_L 4 have the following amino acid sequences respectively;

FR_L 1;

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys (SEQ ID No;

     69);

FR_L 2;

Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr (SEQ ID NO;

     70);

FR_L 3;

Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys (SEQ ID NO;

     71); and

FR_L 4;

Phe Gly Gln Gly Thr Lys Val Glu Ile Lys (SEQ ID NO;

     72);

and the CDR_L 1, CDR_L 2 and CDR_L 3 have the following amino acid sequences respectively;

CDR_L 1;

Arg Ala Ser Glu Asn Ile Tyr Ser Asn Leu Ala (SEQ ID NO;

     62)

CDR_L 2;

Ala Ala Thr Tyr Leu Ala Asp (SEQ ID NO;

     63)

CDR_L 3;

Gln His Phe Trp Gly Thr Pro Pro (SEQ ID NO;

     64) or

wherein the L chain V region is represented by the nucleotide sequence shown in SEQ ID NO;

56; and

the DNA sequence coding for a heavy (H) chain of an antibody to human interleukin-6, wherein the H chain comprises an H chain V region and a human H chain C region wherein the H chain V region is represented by the formula (II);

space="preserve" listing-type="equation">FR.sub.H 1-CDR.sub.H 1-FR.sub.H 2-CDR.sub.H 2-FR.sub.H 3-CDR.sub.H 3-FR.sub.H 4

wherein the FR_H 1, FR_H 2, FR_H 3 and FR_H 4 have one of sets ((a) or (b)) of the following amino acid sequences respectively;

(a) FR_H 1;

Gln Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Arg Pro Thr Gln Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser (SEQ ID NO;

     76);

FR_H 2;

Trp Ile Arg Gln Pro Pro Gly Glu Ala Leu Glu Trp Leu Ala (SEQ ID NO;

     77);

FR_H 3;

Arg Leu Ala Val Ser Lys Asp Thr Ser Lys Asn Gln Val Val Leu Ser Met Asn Thr Val Gly Pro Gly Asp Thr Ala Thr Tyr Tyr Cys Ala Arg (SEQ ID NO;

     78); and

FR_H 4;

Trp.Gly Gln Gly Ile Leu Val Thr Val Ser Ser (SEQ ID NO;

     79) or

(b) FR_H 1;

Gln Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Arg Pro Thr Gln Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Asn (SEQ ID NO;

     80);

FR_H 2;

Trp Ile Arg Gln Pro Pro Gly Glu Ala Leu Glu Trp Leu Ala (SEQ ID NO;

     81);

FR_H 3;

Arg Leu Ala Val Ser Lys Asp Thr Ser Lys Asn Gln Val Val Leu Ser Met Asn Thr Val Gly Pro Gly Asp Thr Ala Thr Tyr Tyr Cys Ala Arg (SEQ ID NO;

     82); and

FR_H4 ;

Trp Gly Gln Gly Ile Leu Val Thr Val Ser Ser (SEQ ID NO;

     83);

and the CDR_H 1, CDR_H 2, and CDR_H 3 have the following amino acid sequences respectively;

CDR_H 1;

Thr Ser Gly Met Thr Val Gly (SEQ ID NO;

     73);

CDR_H 2;

His Ile Trp Trp Asn Asp Asp Lys Tyr Tyr Asn Pro Ala Leu Lys Gly (SEQ ID NO;

     74);

CDR_H 3;

Met Glu Asp Tyr Asp Glu Ala Met Asp Tyr (SEQ ID NO;

     75) or

wherein the H chain V region comprises the nucleotide sequence shown in SEQ ID NO;

60.

3. An isolated transformant containing the recombinant vector according to claim 2.

4. A process for the production of an antibody to human interleukin-6 using gene recombination technology, comprising:

culturing the transformant according to claim 3 under conditions sufficient to produce the antibody, and

isolating the desired antibody produced.

8. A process for the production of an antibody to human interleukin-6 using gene recombination technology, comprising:

culturing the transformant according to claim 3 under conditions sufficient to produce the antibody, and isolating the desired antibody produced.